SOAT2 Inhibitors

The chemical class known as SOAT2 inhibitors encompasses compounds that can interact with and modulate the activity of the sterol O-acyltransferase 2 enzyme. SOAT2 is involved in the esterification of cholesterol, converting free cholesterol into cholesteryl esters for storage in cells. While direct inhibition of SOAT2 would involve compounds that specifically bind to and reduce the enzyme's activity, an indirect approach entails modulating the availability of substrates or altering related pathways that ultimately influence SOAT2 function.

Compounds known to inhibit ACAT (acyl-CoA:cholesterol acyltransferase), which shares functional similarities with SOAT2, can have a secondary impact on SOAT2 activity by shifting the cellular balance of cholesterol esterification. For example, avasimibe and Sandoz 58-035 are known ACAT inhibitors that could indirectly affect SOAT2 by competing for similar substrates or altering the regulatory environment within the cell. On the other hand, the class of compounds known as statins, which includes simvastatin, pravastatin, lovastatin, atorvastatin, rosuvastatin, fluvastatin, pitavastatin, and cerivastatin, primarily function by inhibiting HMG-CoA reductase, the rate-limiting enzyme in cholesterol biosynthesis. By lowering the endogenous production of cholesterol, these statins may reduce the substrate availability for SOAT2, thereby indirectly diminishing its activity. Additionally, compounds like ezetimibe and probucol operate through distinct mechanisms but can still influence SOAT2 activity. Ezetimibe specifically targets the Niemann-Pick C1-like 1 protein on intestinal cells, reducing the absorption of dietary cholesterol. This reduction in cholesterol uptake can lead to decreased substrate levels for SOAT2 in hepatic and extrahepatic tissues.